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Abstract Aggrecanases are considered to play a key role in the
destruction of articular cartilage during the progression of ar-
thritis. Here we report that the N-terminal inhibitory domain of
tissue inhibitor of metalloproteinases 3 (N-TIMP-3), but not
TIMP-1 or TIMP-2, inhibits glycosaminoglycan release from
bovine nasal and porcine articular cartilage explants stimulated
with interleukin-1K or retinoic acid in a dose-dependent manner.
This inhibition is due to the blocking of aggrecanase activity
induced by the catabolic factors. Little apoptosis of primary
porcine chondrocytes is observed at an e¡ective concentration
of N-TIMP-3. These results suggest that TIMP-3 may be a
candidate agent for use against cartilage degradation.
) 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The aggregating proteoglycan, aggrecan, and collagen type
II are the major components of the articular cartilage extra-
cellular matrix. Diseases such as rheumatoid arthritis and os-
teoarthritis are associated with increased degradation of these
macromolecular components [1,2]. This degradation is due to
elevated proteolytic enzyme activities. Loss of aggrecan occurs
initially, followed by mechanical failure of the tissue and col-
lagen degradation [2]. Thus, aggrecan loss is considered to be
a crucial early event in the progression of arthritic disease
[3,4].
Two di¡erent groups of proteinases are thought to be in-
volved in the degradation of aggrecan: matrix metalloprotei-
nases (MMPs) and aggrecanases [3,4]. MMPs cleave the ag-
grecan core protein at the Asn341^Phe342 bond [5], whereas
aggrecanases cleave the Glu373^Ala374 bond [6]. Aggrecanases
are metalloproteinases that belong to the ADAMTS (a dis-
integrin and metalloproteinase with thrombospondin motifs)
family and four ADAMTSs (ADAMTS-1, -4, -5, and -9) have
been shown to cleave aggrecan [7^10]. Both MMP- and ag-
grecanase-generated aggrecan fragments have been identi¢ed
in cartilage explant cultures in vitro [11], as well as in human
synovial £uid and cartilage tissues [12^15].
We have recently reported that tissue inhibitor of me-
talloproteinases 3 (TIMP-3) inhibits ADAMTS-4 and
ADAMTS-5 with Ki values in the subnanomolar range [16].
Hashimoto et al. [17] also reported similar results for
ADAMTS-4 with TIMP-3. Therefore, we have investigated
whether TIMP-3 can inhibit aggrecanases when added exoge-
nously to cultured cartilage tissue explants. We chose two
well-characterized model systems of aggrecan degradation
for our study: bovine nasal and porcine articular cartilage
explants stimulated with interleukin-1K (IL-1K) or retinoic
acid [18,19]. This study demonstrates that N-terminal inhibi-
tory domain of TIMP-3 (N-TIMP-3) inhibits aggrecan degra-
dation in both cartilage explant systems, suggesting that
TIMP-3 may potentially be used as a cartilage protective
agent.
2. Materials and methods
2.1. Reagents and antibodies
Materials were purchased from the following sources: Dulbecco’s
modi¢ed Eagle’s medium (DMEM) and penicillin/streptomycin from
Biowhittaker (Berkshire, UK); amphotericin B from Gibco (Paisley,
UK); fetal calf serum from Labtech International (East Sussex, UK);
chondroitinase ABC and keratanase from Seikagaku (Tokyo, Japan);
anti-rabbit alkaline phosphatase (AP)-linked antibody, anti-mouse
AP-linked antibody, and AP substrate (5-bromo-4-choloro-3-indolyl-
1-phosphate and nitroblue tetrazolium) from Promega (Southampton,
UK); dimethylmethylene blue (DMMB), shark chondroitin sulfate,
retinoic acid, and type 1A bacterial collagenase from Sigma-Aldrich
Company Ltd. (Dorset, UK); pronase E from BDH (Dorset, UK);
propidium iodide/annexin V-£uorescein isothiocyanate conjugate
(V-FITC) kit from Alexis Biochemicals (Nottingham, UK); and
pre-stained Precision Protein Standards1 for sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis (SDS^PAGE) from BioRad
(Hemel Hempstead, UK). Recombinant N-TIMP-1 and N-TIMP-3
were expressed in Escherichia coli and folded from the inclusion
bodies as described previously [16,20]. TIMP-2 was expressed in
HEK 293/EBNA cells and puri¢ed from the conditioned media as
described [21]. Monoclonal antibodies BC-3 (raised against the aggre-
canase-generated aggrecan neoepitope ARGSV) and BC-14 (raised
against the MMP-generated aggrecan neoepitope FFGVG) were gen-
erated and characterized as described previously [22]. Puri¢ed IL-1K
was a gift from Professor J. Saklatvala (Imperial College London,
UK). Bovine nasal septum and porcine metacarpophalangeal joints
were supplied by Fresh Tissue (London, UK) and dissected on site
within 24 h of slaughter.
2.2. Cartilage culture and inhibition studies
Porcine articular cartilage from the metacarpophalangeal joints of
3^9-month-old pigs was dissected into small shavings approximately
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3 mm long and 2^3 mm wide. Bovine nasal cartilage was dissected
into small discs approximately 1 mm in diameter and 1^2 mm in
height. After dissection, the cartilage was allowed to rest for 24 h at
37‡C under 5% CO2 in DMEM containing penicillin/streptomycin,
amphotericin B, and 5% fetal calf serum. The medium was then re-
freshed and the cartilage was rested for a further 24^48 h. Each
cartilage piece was placed in one well of a round bottom 96-well plate
with 200 Wl of serum-free DMEM with or without 10^100 ng/ml
IL-1K or 1 WM retinoic acid and various concentrations of each
TIMP. After 3 days, the conditioned media were harvested and stored
at 320‡C until use.
2.3. Primary chondrocyte isolation and culture
Porcine chondrocytes were isolated by digesting porcine articular
cartilage with pronase E (1 mg/ml for 1 h at 37 ‡C) followed by
bacterial collagenase (1 mg/ml for 5 h at 37‡C). The cells were col-
lected by passing the tissue through a cell strainer, washed twice with
DMEM, and cultured in DMEM containing penicillin/streptomycin,
amphotericin B, and 10% fetal calf serum. The next day, the cells were
washed once with serum-free DMEM and then triplicate cultures were
incubated in fresh media containing 0.5% fetal calf serum with or
without each TIMP for 3 days. Chondrocyte viability and apoptosis
were examined as described in Sections 2.6 and 2.7.
2.4. Analysis of glycosaminoglycan (GAG) release
GAG released into the conditioned medium was measured in du-
plicate using a modi¢cation of the DMMB assay as described by
Farndale et al. [23]. Shark chondroitin sulfate (0^2.62 Wg) was used
as the standard. The percentage of total GAG released into the me-
dium was calculated as follows: % of total GAG released= (total
GAG in the medium)/(total GAG in the medium+total GAG remain-
ing in the cartilage). Equivalent results were obtained irrespective of
whether the data were analyzed as the percentage of total GAG re-
leased or the amount of GAG released into the conditioned medium.
All data were analyzed by unpaired one-tail t tests with Welch’s cor-
rection using the software package GraphPad Prism (San Diego, CA,
USA).
2.5. Identi¢cation of aggrecanase- and MMP-generated aggrecan
fragments by Western analysis
Aggrecan fragments released into the conditioned medium were
deglycosylated using chondroitinase ABC and keratanase. The sam-
ples were then subjected to SDS^PAGE on 6% total acrylamide gels
using the AMMEDIOL bu¡er system [24] and Western blotting anal-
ysis as described by Little et al. [19]. Pre-stained Precision Protein
Standards1 from BioRad were used. The primary antibodies used
to detect aggrecanase-generated and MMP-generated aggrecan frag-
ments were BC-3 and BC-14, respectively [22]. Antigen^antibody
complexes were detected by anti-mouse AP-linked donkey antibody
and the AP substrate.
2.6. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay
Chondrocytes were seeded at 2.5U104 cells per well in a 96-well
plate and treated as described in Section 2.3. Following the 3-day
treatment, sterile-¢ltered MTT in phosphate-bu¡ered saline (PBS)
was added (0.5 mg/ml ¢nal concentration) and incubated for 4 h at
37‡C. A ¢nal concentration of 5% SDS/5 mM HCl was then added to
solubilize the formazan product and incubated overnight at 37‡C in a
shaking incubator. The absorbance was read at 590 nm.
2.7. Propidium iodide/annexin V staining of chondrocytes
Chondrocytes were seeded at 4U105 cells per well in a 48-well plate
and treated as described in Section 2.3. Following the 3-day treat-
ment, the cells were harvested from the plate by scraping. The cells
were washed with PBS, spun, resuspended in 195 Wl of binding bu¡er
(10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2)
and then reacted with 5 Wl of annexin V-FITC for 10 min at room
temperature. Next, the cells were washed with PBS, resuspended in
binding bu¡er and reacted with propidium iodide at a ¢nal concen-
tration of 2 Wg/ml immediately before analysis using a Becton-Dick-
inson LSR £ow cell cytometer.
3. Results
3.1. N-TIMP-3 inhibits IL-1K- and retinoic acid-stimulated
aggrecan breakdown in cartilage explants
Bovine nasal cartilage explants were stimulated with IL-1K
in the presence or absence of N-TIMP-1, TIMP-2, or
N-TIMP-3 for 3 days. Explants treated with IL-1K alone
showed an approximately ¢ve-fold increase in GAG release
over controls (Fig. 1A). The IL-1K-stimulated release was
signi¢cantly inhibited by the addition of N-TIMP-3 in a con-
centration-dependent manner. However, N-TIMP-1 and
TIMP-2 were not e¡ective even at 1 WM. Safranin O staining
of the cartilage explants after treatment with IL-1K revealed
Fig. 1. N-TIMP-3 Inhibition of GAG release from cartilage stimulated with IL-1K or retinoic acid. A: Bovine nasal cartilage explants were
treated with IL-1K (100 ng/ml) in the presence of TIMP for 3 days. The GAG released into the media was measured using the DMMB assay.
The results are from three separate experiments S S.E.M. (n=3 for each experiment). B: Porcine articular cartilage explants were treated with
1 WM retinoic acid in the presence of TIMP for 3 days. The conditioned media were harvested and the released GAG was measured as above.
The results are from three separate experimentsS S.E.M. (n=3 for each experiment). *P9 0.05 as compared with the IL-1K or retinoic acid
treatment without the inhibitor.
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that the addition of N-TIMP-3 protected against the release
of GAGs from the matrix (data not shown). Similar results
were observed with IL-1K-stimulated porcine articular carti-
lage explants (data not shown).
The GAG release from porcine articular cartilage explants
stimulated with retinoic acid was also inhibited by N-TIMP-3,
but to a lesser extent compared with the IL-1K-stimulated
cartilage (Fig. 1B). N-TIMP-1 and TIMP-2 did not inhibit
retinoic acid-stimulated GAG release.
3.2. Aggrecanase activity is speci¢cally inhibited by N-TIMP-3
Conditioned media from the experiments above were ana-
lyzed using monoclonal antibodies that recognize either the
aggrecanase-generated aggrecan neoepitope ARGSV or the
MMP-generated aggrecan neoepitope FFGVG. In concor-
dance with the GAG release data, there was an increase in
the amount of aggrecanase-generated aggrecan fragments re-
leased upon treatment with either stimulus (Fig. 2A,B). No
MMP-generated fragments were detected (data not shown).
The release of aggrecanase-generated fragments was partially
inhibited by 0.05 WM N-TIMP-3 and completely blocked by
0.1 WM N-TIMP-3 in both IL-1K- and retinoic acid-stimulated
cartilage (Fig. 2). N-TIMP-1 and TIMP-2 were not e¡ective
even at 1 WM.
Fig. 2. Detection of aggrecanase-generated aggrecan fragments by
the anti-ARGSV neoepitope antibody. A: Analysis of the condi-
tioned media from bovine cartilage explants treated with IL-1K as
in Fig. 1A. The samples, each containing 40 Wg GAG, were degly-
cosylated and analyzed by Western blotting using an anti-ARGSV
antibody as described in the Section 2.5. B: Analysis of the condi-
tioned media from porcine articular cartilage explants treated with
1 WM retinoic acid as in Fig. 1B. The conditioned media, each con-
taining 30 Wg GAG, were deglycosylated and analyzed by Western
blotting using an anti-ARGSV antibody as in A.
Fig. 3. Inhibition of GAG release by N-TIMP-3 after pre-treatment
of cartilage with IL-1K. Porcine articular cartilage explants were
treated with 10 ng/ml IL-1K for a period of 2 days. The conditioned
media were then removed and replaced with fresh DMEM contain-
ing IL-1K plus various concentrations of N-TIMP-3 for further
3 days. The GAG released into the media was measured using the
DMMB assay. The results are from a representative experiment
(n=3). *P9 0.05 as compared with the IL-1K treatment without the
inhibitor.
Fig. 4. Analysis of chondrocyte viability. Porcine articular chondro-
cytes were cultured in the presence of various concentrations of
N-TIMP-3 for 3 days. The MTT assay was then carried out to test
cell viability as described in Section 2.6. A: Cells following the incu-
bation with MTT. B: The change in the absorbance of each treat-
ment (n=3).
FEBS 27877 8-12-03
C. Gendron et al./FEBS Letters 555 (2003) 431^436 433
3.3. E¡ect of N-TIMP-3 treatment before and after IL-1K
stimulation of cartilage
To investigate the protective e¡ect of TIMP-3, porcine car-
tilage explants were treated with 0.1 or 1 WM N-TIMP-3 for
various periods of time prior to IL-1K stimulation. Each car-
tilage piece was then washed twice using serum-free DMEM
and stimulated with IL-1K for 3 days in the absence of
N-TIMP-3. The amount of GAG released into the condi-
tioned media was subsequently measured. When 0.1 WM
N-TIMP-3 was added, about 50% inhibition was observed
after a 30-min pre-incubation and 72% after a 24-h pre-incu-
bation. In the case of 1 WM N-TIMP-3, a 30-min pre-incuba-
tion was su⁄cient to give s 70% inhibition, and complete
inhibition was achieved with an 8-h pre-incubation. This in-
dicates that the cartilage adsorbs N-TIMP-3 reasonably rap-
idly, and the continuous presence of N-TIMP-3 in the me-
dium during the 3-day IL-1K stimulation is not necessary.
To further test the e¡ectiveness of TIMP-3 protection
against cartilage degradation, porcine cartilage explants were
¢rst treated with 10 ng/ml IL-1K for 2 days and then 0.01, 0.1
or 1 WM N-TIMP-3 with IL-1K for 3 days. Each N-TIMP-3
concentration was able to signi¢cantly inhibit further GAG
release (Fig. 3). In these cases, N-TIMP-3 was slightly more
e¡ective as compared to the earlier experiments where the
inhibitor and IL-1K were added together from the beginning.
3.4. E¡ect of N-TIMP-3 on chondrocyte apoptosis
TIMP-3 causes apoptosis in a variety of cell types including
rat vascular smooth muscle, HeLa, colon carcinoma, and mel-
anoma cells [25^27]. We therefore examined whether the inhi-
bition of GAG release from stimulated cartilage explants by
N-TIMP-3 was due to chondrocyte apoptosis. For this pur-
pose, primary porcine chondrocytes were incubated with var-
ious concentrations of N-TIMP-3 for a period of 3 days. The
cells were then assessed for cell viability using MTT (Fig. 4) or
for apoptosis using propidium iodide/annexin V-FITC stain-
ing (Fig. 5). As a positive control for cell death, chondrocytes
were treated with sodium nitroprusside (SNP). The MTT as-
say indicated that overall cell viability did not change in the
presence of N-TIMP-3 at concentrations up to 1 WM. Propi-
dium iodide/annexin V-FITC staining showed that there was
no signi¢cant increase in chondrocyte apoptosis up to 1 WM
N-TIMP-3 (Fig. 5). Other cell death assays measuring caspase
activation and TUNEL staining con¢rmed these results (data
not shown).
4. Discussion
Previous studies have shown that TIMP-3 is a potent in-
hibitor of ADAMTS-4 and ADAMTS-5 with an apparent Ki
of 3.3 and 0.66 nM, respectively [16,17]. In this report, we
have provided evidence that TIMP-3 e¡ectively prevented
the breakdown of aggrecan in bovine nasal and porcine artic-
ular cartilage explants stimulated by IL-1K or retinoic acid.
The use of neoepitope antibodies to identify proteolytic frag-
ments of the aggrecan core protein indicated that aggre-
canase-mediated degradation of aggrecan was inhibited by
N-TIMP-3.
N-TIMP-1 and TIMP-2 inhibit MMPs with low nanomolar
Ki values, but their inhibitory activities for aggrecanases are
weak. The IC50 value of TIMP-1 for aggrecanase activity
from bovine cartilage was reported to be 210 nM [18] and
those of TIMP-1 and TIMP-2 for ADAMTS-4 are 350 and
420 nM, respectively [17]. Bonassar et al. [28] reported a par-
tial inhibition of GAG loss from IL-1L-treated bovine carti-
lage by 4 WM TIMP-1. These authors also estimated that
approximately 10% or less TIMP-1 (V400 nM) is incorpo-
rated into the tissue based on their measurements of partition-
ing TIMP into adult cartilage [28]. This concentration is sim-
ilar to the IC50 values reported for TIMP-1 inhibition of
aggrecanase activity. It is not clear what proportions of
N-TIMP-1 and TIMP-2 in the medium penetrate the cartilage,
but their concentrations would be su⁄cient to inhibit most
MMPs given their low to subnanomolar inhibition constants
[29]. Lack of inhibition of the stimulated GAG release by
TIMP-1 and TIMP-2 therefore suggests that MMPs are not
involved in aggrecan degradation during the culture period we
examined. These observations agree well with those reported
by Little et al. [11] indicating that MMPs do not participate in
aggrecan degradation until after 3 weeks of culture.
Currently four ADAMTSs (ADAMTS-1, -4, -5, and -9)
have been shown to digest aggrecan core protein at the
Glu373^Ala374 bond, a typical aggrecanase site [7^10]. While
it is yet to be investigated which of the ADAMTSs are the
major enzymes involved in aggrecan degradation in these two
models of cartilage catabolism, our TIMP-3 inhibition studies
suggest that there are at least two pathways for GAG release:
one that is aggrecanase dependent and the other that is
aggrecanase independent. Western blotting with the anti-
ARGSV antibody indicated a clear dose-dependent inhibition
of aggrecanase activity by TIMP-3 in both IL-1K- and retinoic
acid-stimulated cartilage, but they did not exactly match
TIMP-3 inhibition of GAG release (see Figs. 1 and 2). This
di¡erence was more prominent in cartilage stimulated with
retinoic acid than with IL-1K-treated cartilage. For example,
0.05 WM of TIMP-3 exhibited little inhibition of GAG release
Fig. 5. Analysis of chondrocyte apoptosis. Porcine articular chon-
drocytes were incubated with various concentrations of N-TIMP-3
for 3 days. The cells were harvested, stained with propidium iodide
and annexin V-FITC, and analyzed using £ow cytometry. The num-
ber in each quadrant indicates the percentage of cells in that area
(n=3). The lower right and upper right quadrants indicate the per-
centage of chondrocytes in early and late apoptosis, respectively.
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from retinoic acid-stimulated cartilage, but it e¡ectively inhib-
ited aggrecanase activity. A possible mechanism of aggreca-
nase-independent GAG release may be due to the action of
hyaluronidases as proposed by Sztrolovics et al. [30,31].
Pre-treatment of cartilage with 1 WM TIMP-3 for a mini-
mum of 30 min followed by removal of the inhibitor before
IL-1K-stimulation is su⁄cient to signi¢cantly inhibit aggrecan
catabolism. This is most likely due to TIMP-3 binding to the
cartilage matrix. Factors that may in£uence the ability of
N-TIMP-3 to enter the cartilage matrix include its basic pI of
9.27 and its a⁄nity for polyanionic components of the extra-
cellular matrix [32]. Even more e¡ective inhibition of GAG
release was observed by adding N-TIMP-3 to the cartilage
after 2 days of stimulation with IL-1K. The reason for this
observation is not clear, but it may be that N-TIMP-3 can
penetrate the tissue more readily when the cartilage matrix is
partially degraded and therefore block aggrecanase activity
more e¡ectively.
A number of studies have indicated that TIMP-3 causes
apoptosis of several cell types [26,33,34], while TIMP-1 and
TIMP-2 have anti-apoptotic activity [35^37]. N-TIMP-3-in-
duced apoptosis correlates with the stabilization of TNFK,
Fas, and TNFK-related apoptosis inducing ligand receptors
on the cell surface [26,33,34]. It is also dependent on Fas-
associated death domain [38]. In our study on isolated pri-
mary chondrocytes, no signi¢cant apoptosis was observed
even at 1 WM N-TIMP-3. Therefore, inhibition of aggrecan
breakdown by N-TIMP-3 was due solely to the inhibition of
metalloproteinases.
Various anti-rheumatic compounds may enhance the pro-
duction of TIMP-3 as a mechanism of disease relief. For
example, calcium pentosan polysulfate has been shown to
relieve the symptoms of osteoarthritis [39] and Takizawa et
al. have demonstrated that the addition of calcium pentosan
polysulfate to human rheumatoid synovial ¢broblasts in-
creased TIMP-3 protein levels without an increase in
mRNA levels [40]. Furthermore, the addition of calcium pen-
tosan polysulfate was shown to inhibit aggrecan catabolism in
bovine articular cartilage explants [41]. Heparinoid, a compo-
nent of the anti-rheumatic drug Mobilat, was also shown to
increase the amount of TIMP-3 protein in the presence of
IL-1K via a mechanism that was independent of mRNA levels
[42]. Other work has demonstrated that the adenoviral expres-
sion of TIMP-3 in rheumatoid synovial ¢broblasts signi¢-
cantly inhibits the invasion of the pannus into the cartilage
matrix [43]. These studies support the notion that TIMP-3
plays a pivotal role in ameliorating arthritis. The data re-
ported herein provides direct evidence that TIMP-3 protects
the articular joint against cartilage degradation. Therefore,
TIMP-3 can be considered as a potential chondroprotectant
in cartilage degenerative diseases such as osteoarthritis.
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